Anticancer medicines in Pakistan: An analysis of essential medicines lists
Journal of Oncology Pharmacy Practice · 2024
DOI: 10.1177/10781552231167809 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Sundus Shukar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drugs, Essential. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Objective
The lack of anticancer drugs for curative and supportive purposes is the critical reason for the low survival rate in low-and-middle-income countries. This study aims to analyze whether the National Essential Medicines List (NEML) and Registered Essential Medicines List (REML) are in concordance with the World Health Organization (WHO) Essential Medicines List (EML) and whether the formularies prevalent in the country are parallel to each other and to the NEML.
Method
An observational study design was used in which antineoplastic drugs from the 2021 NEML and REML were compared with 2021 WHO EML to evaluate their availability in Pakistan. Market access was determined. Moreover, the formularies of six different hospital types were compared with each other and with the NEML, and REML to estimate the availability within hospitals.
Results
There were 66 anticancer drugs in 2021 WHO EML and all were found in Pakistan's 2021 NEML but only 48 drugs (73%) were found in the REML. Hydroxycarbamide and dasatinib were two registered drugs absent in all hospitals’ formularies. The market access for anticancer medicines was 73% (48 of 66). Semigovernment hospital (86%) has the highest availability, followed by the government hospital (80%). All the hospitals have unregistered drugs including bortezomib, lenalidomide, and mesna.
Conclusion
Pakistan's NEML adopts WHO EML abruptly but all medicines are not registered. The hospitals are trying their best to increase availability but optimum drug regulations to revise NEML based on the country's requirements and emphasizing registration of anticancer medicines are needed to improve the country's availability of antineoplastic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Center for Drug Safety and Policy Research, Xian Jiaotong University, Xi'an, Shaanxi, China.
- Department of Pharmacy, Shifa International Hospitals, Islamabad, Pakistan.
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
- Department of Pharmacy, Samaa Fertilization Center Jumeriah, Dubai, United Arab Emirates.
ORCID-Profile: Sundus Shukar, Caijun Yang
Zitieren
APA
Shukar, S., Anjum, R., Zhang, J., Babar, Z. U., Mobeen, I., & Yang, C. (2024). Anticancer medicines in Pakistan: An analysis of essential medicines lists. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231167809
Vancouver
Shukar S, Anjum R, Zhang J, Babar ZU, Mobeen I, Yang C. Anticancer medicines in Pakistan: An analysis of essential medicines lists. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552231167809
BibTeX
@article{Shukar2024,
author = {Shukar, Sundus and Anjum, Rehan and Zhang, Jinwei and Babar, Zaheer-Ud-Din and Mobeen, Iqra and Yang, Caijun},
title = {Anticancer medicines in Pakistan: An analysis of essential medicines lists},
journal = {Journal of Oncology Pharmacy Practice},
year = {2024},
doi = {10.1177/10781552231167809}
}
EUVIMED